Galapagos signs two new drug discovery collaborations with Ono Pharmaceutical
16 April 2007 - 5:01PM
UK Regulatory
Mechelen, Belgium and Osaka, Japan; 16 April 2007 - Galapagos NV
(Euronext & LSE: GLPG) announced today that its BioFocus DPI service
division has signed two new collaborations with Ono Pharmaceutical
Company Ltd. (Tokyo: OSA). These collaborations build on the
successful relationship between Ono and DPI, which began in 2004.
Under the first collaboration announced today, BioFocus DPI will use
selected compounds from its SoftFocus and other synthetic small
molecule collections to perform high throughput screening for Ono's
drug discovery program. In the second collaboration, BioFocus DPI
will apply its medicinal and computational chemistry and ADME
profiling expertise in multiple medicinal chemistry projects for Ono.
"We are pleased with the new contracts with Ono that build on the
longstanding relationship between Ono and DPI. The new contracts
show the benefit of building a global drug discovery service
business. We combine expertise from our acquired companies Discovery
Partners International, BioFocus as well as Inpharmatica, realizing
the synergy in bringing these activities together," added Onno van de
Stolpe, Chief Executive Officer of Galapagos.
"We are dedicated to creating innovative medicines," said Dr.
Daikichi Fukushima, Managing Director, Ono. "Accordingly, we are
enthusiastic about extending the relationship with BioFocus DPI, a
leading company in drug discovery, so that we can continue creating
novel drug candidates."
About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London
AiM: GLPG) is a drug discovery company with clinical and pre-clinical
programs in bone and joint diseases, cachexia, and menopausal hot
flashes. Its division BioFocus DPI offers a full suite of
target-to-drug discovery products and services to pharmaceutical and
biotech companies, encompassing target discovery and validation,
screening and drug discovery through to delivery of pre-clinical
candidates. BioFocus DPI also provides adenoviral reagents for rapid
identification and validation of novel drug targets, compound
libraries for drug screening as well as chemogenomics and ADMET[1]
database products to select targets and compounds. Galapagos
currently employs 450 people and operates facilities in eight
countries, with global headquarters in Mechelen, Belgium. More
information about Galapagos and BioFocus DPI can be found at
www.glpg.com.
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions,
performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.
[1] ADMET is the acronym for Absorption, Distribution, Metabolism,
Excretion, and Toxicity: Meeting parameters against these five
criteria is critical to the success of a pharmaceutical compound as a
drug.
Copyright � Hugin ASA 2007. All rights reserved.
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024